High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
Abstract Background Malignant glioma is the most common primary brain tumor in adults and has a poor prognosis. However, there are no effective targeted therapies for glioma patients. Thus, the development of novel targeted therapeutics for glioma is urgently needed. Methods In this study, we examin...
Main Authors: | Chenglong Yue, Mingshan Niu, Qian Qian Shan, Ting Zhou, Yiming Tu, Peng Xie, Lei Hua, Rutong Yu, Xuejiao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-017-0600-7 |
Similar Items
-
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01) -
Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells
by: Emilie Logie, et al.
Published: (2021-03-01) -
Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders
by: Huimin Qiao, et al.
Published: (2022-06-01) -
Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
by: Huanan Rao, et al.
Published: (2022-11-01) -
HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
by: Ziwen Lu, et al.
Published: (2022-06-01)